Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes

Endocrine Journal

Volumn 58, Issue 12, 2011, Pages 1055-1063

  Naruse, Rika ^a   Takebayashi, Kohzo ^a   Morita, Kimio ^a   Aso, Yoshimasa ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Insulin; Oxidative stress; Type 2 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; GLUCOSE; INSULIN ASPART; INSULIN DETEMIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DINOPROST; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84855165628     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-114     Document Type: Article

References (30)

1. The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405.
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) The Funagata Diabetes Study. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22:920-924.
3. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20 year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367.
4. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW (2002) Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845-1850.
5. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL (2001) Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 24:1397-1402.
6. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240.
7. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M (2006) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91:813-819.
8. Bavenholm PN, Efendic S (2006) Postprandial hyperglycemia and vascular damage-the benefits of acarbose. Diabetes Vasc Dis Res 3:72-79.
9. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687.
10. Brownlee M (2005) The pathology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625.
11. Ceriello A (2003) The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46: M9-16.
12. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A (2001) Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281:E924-E930.
13. Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campalgne BN, Kerr L, Milicevic Z, Jacober SJ (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care 32:381-386.
14. Aljada A, Ghanim H, Saadeh R, Dandona P (2001) Insulin inhibits NfkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86:450-453.
15. Dandona P, Aljada A, Mohanty P, Ghaim H, Hamouda W, Assian E, Ahmad S (2001) Insulin inhibits intranuclear NFkB and stimulates IkB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265.
16. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P (2002) Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87:1419-1422.
17. Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P (2004) Antiinflammatory and pro-fibronolytic effect of insulin in acute ST-elevation myocardial infarction. Circulation 109:849-854.
18. Wong VW, McLean M, Boyages SC, Cheung NW (2004) C-reactive protein levels following acute myo cardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care 27:2971-2973.
19. Patrono C, Fitzgerald GA (1997) Isoprostanes: potential markers of oxidative stress in arterothrombotic disease. Arterioscler Thromb Vasc Biol 17:2309-2315.
20. Treatment guide for diabetes edited by Japan Diabetes Society 2007. Bunkodo, Tokyo, Japan
21. Helmersson J, Basu S (1999) F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids. 61:203-205.
22. Ceriello A, Bonfigli AR, Esposito K, Marra M, Testa R, Giuglino D (2011) The possible protective role of glucagon- like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon- like peptide 1 in diabetes. Diabetes Care 34:697-702.
23. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007) Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92:2712-2719.
24. Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26:881-885.
25. Takebayashi K, Aso Y, Inukai T (2004) Initiation of insulin therapy reduces serum concentrations of highsensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 53:693-699.
26. Hirsch IB (2005) Insulin analogues. N Engl J Med 352: 174-183.
27. Kaku K, Matsuda M, Urae A, Irie S (2000) Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 49:119-126.
28. Jhee SS, Lyness WH, Rojas PB, Leibowitz MT, Zartosky V, Jacobsen LV (2004) Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects. J Clin Pharmacol 44:258-264.
29. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR (2010) Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562-571.
30. Monnier L, Colette C, Michel F, Cristol JP, Owens DR (2011) Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes Metab Res Rev 27:348-353.